FDA DEVICE FACTS
HAART 300 Aortic Annuloplasty Device 19mm, HAART 300 Aortic Annuloplasty Device 21mm, HAART 300 Aortic Annuloplasty Device 23mm, HAART 300 Aortic Annuloplasty Device 25mm
Biostable Science & Engineering, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The HAART 300 Aortic Annuloplasty Device is intended to be used to correct annular dilatation and/or maintain annular geometry of the aortic valve in patients with tri- leaflet valve morphology with moderate to severe aortic insufficiency who are undergoing aortic valve repair due to symptoms or as part of a repair for an aortic root aneurysm.
Summary of Technological Characteristics and Substantial Equivalence
The intended use, technological characteristics, and principles of operation of the HAART 300 Aortic Annuloplasty Device are substantially equivalent to legally marketed mitral and tricuspid annuloplasty devices. More specifically, the HAART 300 Aortic Annuloplasty Device is substantially equivalent to the Carpentier -Edwards Physio Tricuspid Annuloplasty Ring Model 6200 (K103520). The difference between the indications for use of the HAART 300 Device and its predicate is the anatomic position of the valve being treated. However, this has no impact on the therapeutic effect of the device, which is the same as the predicate, which is to reshape and stabilize the valve annulus during surgical reconstruction of valvular insufficiency. The technological characteristics of both devices are equivalent with the exception of the silicon sewing ring added to the Physio Annuloplasty Ring and the material of the thread used to sew the polyester cloth to the device. These differences do not raise different questions of safety and effectiveness. Both devices are provided with accessories that include instruments for sizing the device and a holder to facilitate implantation. The principles of operation including the implantation steps, are also equivalent. Differences in the characteristics do no t present any new issues of safety or effectiveness. Thus, the HAART 300 Aortic Annuloplasty Device is substantially equivalent.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。